Biomarker Research,
Год журнала:
2023,
Номер
11(1)
Опубликована: Апрель 17, 2023
Abstract
N6-methyladenosine
(m
6
A)
is
considered
as
the
most
common
and
important
internal
transcript
modification
in
several
diseases
like
type
2
diabetes,
schizophrenia
especially
cancer.
As
a
main
target
of
m
A
methylation,
long
non-coding
RNAs
(lncRNAs)
have
been
proved
to
regulate
cellular
processes
at
various
levels,
including
epigenetic
modification,
transcriptional,
post-transcriptional,
translational
post-translational
regulation.
Recently,
accumulating
evidence
suggests
that
A-modified
lncRNAs
greatly
participate
tumorigenesis
cancers.
In
this
review,
we
systematically
summarized
biogenesis
identified
A-lncRNAs
variety
cancers,
well
their
potential
diagnostic
therapeutic
applications
biomarkers
targets,
hoping
shed
light
on
novel
strategies
for
cancer
treatment.
Cells,
Год журнала:
2022,
Номер
11(19), С. 3008 - 3008
Опубликована: Сен. 27, 2022
Background:
Long
non-coding
RNAs
modulate
tumor
occurrence
through
different
molecular
mechanisms.
It
had
been
reported
that
HNF1A-AS1
(HNF1A
Antisense
RNA
1)
was
differently
expressed
in
multiple
tumors.
The
role
of
colorectal
cancer
less
analyzed,
and
the
mechanism
regulating
cell
cycle
has
not
completely
elucidated.
Methods:
Differentially
lncRNAs
were
screened
out
from
TCGA
database.
examined
CRC
clinical
samples
lines
by
RT-qPCR.
CCK8
assay,
colony
formation
flow
cytometry,
transwell
assays,
tube
forming
assay
vivo
experiments
performed
to
study
function
progression.
Bioinformatic
analysis,
luciferase
report
pull-down
RIP
assays
carried
explore
proteins
binding
potential
downstream
targets.
Results:
Our
results
showed
upregulated
associated
with
unfavorable
prognosis.
promoted
proliferation,
migration
angiogenesis,
accelerated
reduced
apoptosis
CRC.
Bioinformatics
prediction
further
proved
could
promote
CCND1
expression
suppressing
PDCD4
or
competitively
sponging
miR-93-5p.
Meanwhile,
METTL3
mediated
m6A
modification
affected
its
stability.
HNF1A-AS1/IGF2BP2/CCND1
may
act
as
a
complex
regulate
stability
CCND1.
Conclusion:
In
summary,
our
result
reveals
novel
which
m6A-mediated
axis
promotes
progression,
along
miR-93-5p
upregulate
CCND1,
demonstrating
significant
regulation
suggesting
prognostic
marker
future.
Molecular Oncology,
Год журнала:
2022,
Номер
17(2), С. 195 - 229
Опубликована: Окт. 19, 2022
N
6
‐
methyladenosine
(m
A)
is
one
of
the
most
abundant
internal
modifications
in
eukaryotic
messenger
RNAs
(mRNAs)
and
non‐coding
(ncRNAs).
It
a
reversible
dynamic
RNA
modification
that
has
been
observed
both
coding
segments
untranslated
regions.
Studies
indicate
m
A
play
important
roles
translation,
splicing,
export,
degradation
ncRNA
processing
control.
In
this
review,
we
focus
on
profiles
biological
functions
methylation
mRNAs
ncRNAs.
The
its
potential
cancer
development
are
discussed.
Moreover,
discuss
possibility
serving
as
biomarkers
for
diagnosis
targets
therapy.
Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Март 21, 2023
Long
non-coding
RNAs
(lncRNAs)
are
regulatory
transcripts
with
essential
roles
in
the
pathogenesis
of
almost
all
types
cancers,
including
prostate
cancer.
They
can
act
as
either
oncogenic
lncRNAs
or
tumor
suppressor
ones
Small
nucleolar
RNA
host
genes
among
mostly
assessed
this
PCA3
is
an
example
that
has
been
approved
a
diagnostic
marker
A
number
well-known
other
cancers
such
DANCR,
MALAT1,
CCAT1,
PVT1,
TUG1
and
NEAT1
have
also
shown
to
oncogenes
On
hand,
LINC00893,
LINC01679,
MIR22HG,
RP1-59D14.5,
MAGI2-AS3,
NXTAR,
FGF14-AS2
ADAMTS9-AS1
suppressors
LncRNAs
contribute
cancer
via
modulation
androgen
receptor
(AR)
signaling,
ubiquitin-proteasome
degradation
process
AR
important
signaling
pathways.
The
current
review
summarizes
role
evolution
especial
focus
on
their
importance
design
novel
biomarker
panels
therapeutic
targets.
Abstract
The
incidence
of
prostate
cancer
(PCa),
the
most
prevalent
malignancy,
is
currently
at
forefront.
RNA
modification
a
subfield
booming
field
epigenetics.
To
date,
more
than
170
types
modifications
have
been
described,
and
N6-methyladenosine
(m6A)
abundant
well-characterized
internal
mRNAs
involved
in
various
aspects
progression.
METTL3,
first
identified
key
methyltransferase,
regulates
human
mRNA
non-coding
expression
an
m6A-dependent
manner.
This
review
elucidates
biological
function
role
METTL3
PCa
discusses
implications
as
potential
therapeutic
target
for
future
research
directions
clinical
applications.
Abstract
Background
Exosome-derived
long
non-coding
RNAs
(lncRNAs)
and
N6-methyladenosine
(m
6
A)
modifications
of
lncRNAs
have
been
shown
crucial
functions
in
prostate
cancer
(PCa).
Herein,
we
aim
to
investigate
the
detailed
mechanism
exosome-derived
lncRNA
A1BG-AS1
PCa
process.
Methods
cell
exosomes
were
extracted,
exosomal
marker
proteins
(CD63,
CD9)
detected
utilizing
western
blotting,
with
overexpressing
co-cultured
targeted
cells.
qRT-PCR
was
used
detect
expression
m
A
methyltransferase
ZC3H13
PCa.
Transwell,
colony
formation
CCK-8
assays
utilized
assess
invasion,
migration,
proliferation
ability
Then,
performed
actinomycin
D
MeRIP
analyze
regulatory
effect
on
mRNA
stability
modification
level.
Results
We
observed
that
restricted
tumors.
The
migratory
capacities
cells
could
be
inhibited
by
up-regulating
or
co-culturing
up-regulate
A1BG-AS1.
Additionally,
promoted
stable
regulating
level
Conclusion
Exosomal
A-modified
stabilize
thus
prevent
malignancy.
These
findings
offer
a
possible
target
for
clinical
therapy
Abstract
N
6
-methyladenosine
(m
A)
represents
the
most
prevalent
internal
and
reversible
modification
on
RNAs.
Different
cell
types
display
their
unique
m
A
profiles,
which
are
determined
by
functions
of
writers
erasers.
M
modifications
lead
to
different
outcomes
such
as
decay,
stabilization,
or
transport
The
A-encoded
epigenetic
information
is
interpreted
readers
interacting
proteins.
essential
for
biological
processes,
defects
in
have
been
discovered
diverse
diseases.
Here,
we
review
latest
advances
roles
development
These
recent
studies
not
only
highlight
importance
regulating
fate
transitions,
but
also
point
potential
application
drugs
targeting
